160 related articles for article (PubMed ID: 6432730)
21. [Change in the diagnosis and therapy of Stein-Leventhal syndrome].
Seifert B; Nickel I; Seliger E; Fröhlich R; Petrich G
Zentralbl Gynakol; 1986; 108(6):359-64. PubMed ID: 3087090
[TBL] [Abstract][Full Text] [Related]
22. Plasma endothelin and LH-RH, LH, FSH, prolactin, progesterone, 17alpha-hydroxyprogesterone, estrone, 17beta-estradiol, delta4-androstenedione, testosterone, active renin, angiotensin-II and ANP levels in blood and LH, estrone and 17beta-estradiol and pregnanediol levels in urine of normal cycling women.
Usuki S; Kondoh K; Kubo T
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S421-7. PubMed ID: 11078439
[TBL] [Abstract][Full Text] [Related]
23. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
Song J; Shen H; Li J; Huang Z; Zhang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
[TBL] [Abstract][Full Text] [Related]
24. Effects of unkei-to, an herbal medicine, on endocrine function and ovulation in women with high basal levels of luteinizing hormone secretion.
Ushiroyama T; Ikeda A; Sakai M; Hosotani T; Suzuki Y; Tsubokura S; Ueki M
J Reprod Med; 2001 May; 46(5):451-6. PubMed ID: 11396371
[TBL] [Abstract][Full Text] [Related]
25. [The hormonal profile in the polycystic ovary syndrome].
Donát J; Kohoutek M; Donátová N; Lacinová V
Cesk Gynekol; 1989 Nov; 54(9):684-8. PubMed ID: 2516481
[No Abstract] [Full Text] [Related]
26. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome.
Sönmez AS; Yasar L; Savan K; Koç S; Ozcan J; Toklar A; Yazicioğu F; Akgün A; Sut N
Hum Reprod; 2005 Jan; 20(1):175-9. PubMed ID: 15513975
[TBL] [Abstract][Full Text] [Related]
27. [Circulating levels of LH, FSH and basal steroids in subjects with polycystic ovary syndrome before and after wedge resection of the ovaries].
Ragucci N; Amato G; Izzo A
Arch Ostet Ginecol; 1981; 86(5-6):263-79. PubMed ID: 6819842
[No Abstract] [Full Text] [Related]
28. [Endocrinological aspects of puberal gynecomastia].
Cicognani A; Villa MP; Cassio A; Ventura D; Becca A; Tassinari D; Cacciari E
Minerva Pediatr; 1981 Jun; 33(11):507-14. PubMed ID: 6789052
[No Abstract] [Full Text] [Related]
29. Synergism of pulsatile LHRH therapy with oral clomiphene treatment.
Homburg R; Eshel A; Armar NA; Tucker M; Adams J; Jacobs HS
Gynecol Endocrinol; 1988 Mar; 2(1):59-66. PubMed ID: 3140591
[TBL] [Abstract][Full Text] [Related]
30. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
31. Estradiol-to-testosterone ratio is associated with response to metformin treatment in women with clomiphene citrate-resistant polycystic ovary syndrome (PCOS).
Horng SG; Wang TH; Wang HS
Chang Gung Med J; 2008; 31(5):477-83. PubMed ID: 19097595
[TBL] [Abstract][Full Text] [Related]
32. Alcohol effects on plasma estradiol levels following LHRH administration to women.
Mendelson JH; Mello NK; Teoh SK; Ellingboe J
NIDA Res Monogr; 1989; 95():425. PubMed ID: 2518134
[No Abstract] [Full Text] [Related]
33. Pituitary and ovarian responses to LHRH stimulation in women with clinical features of the polycystic ovary syndrome.
Heineman MJ; Thomas CM; Doesburg WH; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):273-84. PubMed ID: 6430731
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
[TBL] [Abstract][Full Text] [Related]
35. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics.
La Marca A; Orvieto R; Giulini S; Jasonni VM; Volpe A; De Leo V
Fertil Steril; 2004 Oct; 82(4):970-2. PubMed ID: 15482785
[TBL] [Abstract][Full Text] [Related]
36. [Is increased secretion of LH after LHRH administration a reliable indicator of polycystic ovary syndrome?].
Steck T; Petraki S; Baseler C; Albert PJ; Wernze H
Gynakol Rundsch; 1991; 31 Suppl 2():328-31. PubMed ID: 1790969
[No Abstract] [Full Text] [Related]
37. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
38. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
[No Abstract] [Full Text] [Related]
39. [Antiandrogenic effect of spironolactone. I. Studies on spironolactone-induced alterations in the plasma hormonal patterns (author's transl)].
Baba S
Nihon Hinyokika Gakkai Zasshi; 1977 Dec; 68(12):1184-92. PubMed ID: 609174
[No Abstract] [Full Text] [Related]
40. [Retrograde vascular catheterization as a differential diagnostic method of studying androgenization in the female].
Seifert B; Boehlke R; Fröhlich R; Seliger E; Nickel I
Zentralbl Gynakol; 1987; 109(8):487-92. PubMed ID: 3111127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
